ReviewJournal of physiology and biochemistry2026
Glycocalyx degradation: exploring related mechanisms, pathophysiological significance, and therapeutic prospects.
Review in Journal of physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The glycocalyx is a fuzzy structure covering the luminal surface of vascular endothelial cells. Its name was first proposed by Bennett, derived from the Latin word meaning ‘sweet shell’. This was confirmed by Luft in 1966 through ruthenium red staining under electron microscopy. In recent years, the role of the glycocalyx in the pathophysiological processes of various diseases, such as cardiovascular diseases, chronic kidney disease, sepsis, COVID-19 infection, and diabetes, has gradually attracted widespread attention, and its importance has been increasingly recognized. In these acute and chronic clinical situations, the endothelium surface may lose syndecans, heparan sulfate (HS), and hyaluronan (HA), the primary constituents of the glycocalyx, a process involving multiple degrading enzymes. This review aims to start from the mechanisms of glycocalyx degradation, systematically elaborate on the factors related to degradation, enzymes involved in the degradation process, and signaling pathways. It also explores pharmacological drugs with the potential to reduce glycocalyx shedding, as found in current laboratory and clinical studies. In this review, it is expected to provide a reference for a deeper understanding of the role of glycocalyx in physiological and pathological processes and to offer new ideas and targets for the development of diagnostic, therapeutic, and preventive strategies for related diseases.
Indexed as
Identifiers
41801631What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.